Opioid Analgesics Do Not Improve Abdominal Pain or Quality of Life in Crohn’s Disease
- 22 November 2019
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 65 (8) , 2379-2387
Abstract
Background Abdominal pain and opioid analgesic use are common in Crohn’s disease (CD). Aims We sought to identify factors associated with abdominal pain in CD and evaluate the impact of opioid analgesics on pain and quality-of-life scores in this setting. Methods We performed a longitudinal cohort study using a prospective, consented IBD natural history registry from a single academic center between 2009 and 2013. Consecutive CD patients were followed for at least 1 year after an index visit. Data were abstracted regarding pain experience (from validated surveys), inflammatory activity (using endoscopic/histologic findings), laboratory studies, coexistent psychiatric disorders, medical therapy, opioid analgesic, and tobacco use. Results Of 542 CD patients (56.6% women), 232 (42.8%) described abdominal pain. Individuals with pain were more likely to undergo surgery and were more frequently prescribed analgesics and/or antidepressants/anxiolytics. Elevated ESR (OR 1.79; 95%CI 1.11–2.87), coexistent anxiety/depression (OR 1.87; 95%CI 1.13–3.09), smoking (OR 2.08; 95%CI 1.27–3.40), and opioid use (OR 2.46; 95%CI 1.33–4.57) were independently associated with abdominal pain. Eighty patients (14.8%) were prescribed opioids, while 31 began taking them at or after the index visit. Patients started on opioids demonstrated no improvement in abdominal pain or quality-of-life scores on follow-up compared to patients not taking opioids. Conclusions Abdominal pain is common in CD and is associated with significant opioid analgesic utilization and increased incidence of anxiety/depression, smoking, and elevated inflammatory markers. Importantly, opioid use in CD was not associated with improvement in pain or quality-of-life scores. These findings reinforce the limitations of currently available analgesics in IBD and support exploration of alternative therapies.Keywords
Funding Information
- National Institutes of Health (DK063922)
- IBD Working Group
This publication has 51 references indexed in Scilit:
- Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000–2010Medical Care, 2013
- Common Symptoms and Stressors Among Individuals With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2011
- Utilization of healthcare resources by U.S. children and adults with inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Impact of pain on health-related quality of life in patients with inflammatory bowel diseaseWorld Journal of Gastroenterology, 2010
- Pain and inflammatory bowel diseaseInflammatory Bowel Diseases, 2009
- Gender and non‐medical use of prescription opioids: results from a national US survey*Addiction, 2007
- The Narcotic Bowel Syndrome: Clinical Features, Pathophysiology, and ManagementClinical Gastroenterology and Hepatology, 2007
- Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT RegistryClinical Gastroenterology and Hepatology, 2006
- The opioid system in the gastrointestinal tractNeurogastroenterology & Motility, 2004
- Symptoms of irritable bowel syndrome in ulcerative colitis in remissionGut, 1983